Abstract: Provided is a storage container for storing a cornea specimen in which an endothelium and an epithelium of a cornea can be immersed and stored in different storage solutions.

Abstract: A cover (220, 320, 420) for covering a part in a circumferential direction of an outer circumferential surface of a rigid endoscope 10 includes an outer cover portion (222, 322, 422) having flexibility and an inner cover portion (223, 323, 423) provided on an inner surface of the outer cover portion (222, 322, 422) and configured to define a flow passage for a washing fluid to be supplied to an observation window portion 14 of the rigid endoscope 10, and the outer cover portion(222, 322, 422) is mounted onto the outer circumferential surface of the rigid endoscope 10 by the outer cover portion (222, 322, 422) bending.

Abstract: A planar antenna includes a patch conductor formed on a front surface of a dielectric substrate 20 so to be obliquely arranged in relation to an orthogonal axis of the dielectric substrate, the patch conductor having an elliptic shape; a microstrip line 40 for feeding power to a bottom part of the patch conductor; and a ground conductor plate 50 formed on a back surface of the dielectric substrate at a position thereof that is not overlapped with the patch conductor. By forming the patch conductor to be inclined only by ?, circular polarization characteristics in which axial ratio is 3 dB or less are given and the wideband such that the frequency bandwidth in which VSWR characteristics are 2 or less is 2 through 5 GHz and the wideband in UWB High band can be attained. The antenna characteristics in which any radiation directivity on the zenith direction does not depend on the frequency are obtained.

Abstract: According to one embodiment, there is provided a nucleic acid primer set that amplifies a ZEBOV gene. An F1 sequence includes at least 13 consecutive bases included in SEQ ID NO: 31 or 64. An F2 sequence includes at least 13 bases included in SEQ ID NO: 62 or 63. An F3 sequence includes at least 13 bases included in SEQ ID NO: 29, 36, 38, 55, 56, 57, 58, 59, 60, 61 or 61. A B1c sequence includes at least 13 bases included in SEQ ID NO: 68, 69, 70, 71, 72, 73, 74 or 75. A B2c sequence includes at least 13 bases included in SEQ ID NO: 65 or 66. A B3c sequence includes at least 13 bases included in SEQ ID NO: 34, 67, 82 or 83.

Abstract: A series of fluorine-containing bisphosphonic acids in which an alkylamine side chain is added, a series of fluorine-containing bisphosphonic acids in which an amino group substituted by a heterocyclic group or a heterocyclic group containing a nitrogen atom is added, to the carbon atom of P—C(F)—P, and a series of fluorine-containing bisphosphonate derivatives in which the acid moiety thereof is esterified by an alkoxymethyl group such as POM group, n-butanoyloxymethyl (BuOM) group and the like, that is, the fluorine-containing bisphosphonic acid and fluorine-containing bisphosphonate derivative represented by the following formula (I): wherein each symbol is as defined in the DESCRIPTION, can efficiently induce proliferation of peripheral blood ?? T cells that express V?2V?2 T cell receptor having superior cytotoxicity against tumor cells and virus infected cells, immunize tumor cells and virus infected cells, and can induce cytotoxicity by ?? T cells.

Abstract: The present invention relates to a composition containing as its main component proanthocyanidin oligomer to which a substance having a phloroglucinol ring structure or resorcinol ring structure has been bonded and reduced in the molecular weight, which is obtained by heating plant materials containing proanthocyanidin polymer or extract thereof with a substance having a phloroglucinol ring structure or resorcinol ring structure in an acidic aqueous solution, production method thereof, and uses of the composition in health products and pharmaceutical products. According to the invention, proanthocyanidin oligomer having physiological activity, to which a substance having a phloroglucinol ring structure or resorcinol ring structure has been bonded and reduced in the molecular weight to such a level that the oligomer can be absorbed into living body, which has been conventionally difficult to obtain at high yield from plant raw materials, can be produced efficiently and easily.

Abstract: To reduce the risk of damaging organs in a body while delivering a thread during surgery, an instrument for delivering a surgical thread has a grip, an outer cylinder fixed the grip, a hollow needle extending inside the outer cylinder and being configured to be moved relative to the outer cylinder in an axial direction and a loop configured to be housed in the outer cylinder. An end of the outer cylinder is bent in a state where force is not applied. The hollow needle is exposed from the outer cylinder when puncturing skin or etc., and the hollow needle is housed in the outer cylinder when it travels near organs which should not be damaged.

Abstract: A CO sensor includes a solid electrolyte substrate, a sensing electrode, and a reference electrode, and outputs electromotive forces in accordance with CO concentrations. The sensing electrode and the reference electrode are provided on the same surface of the solid electrolyte substrate. The sensing electrode contains a metal oxide such as Bi2O3 that generates a positive electromotive force response when coming into contact with CO. The reference electrode contains a metal oxide such as CeO2 that generates a negative electromotive force response when coming into contact with CO.

Abstract: A planar antenna includes a patch conductor formed on a front surface of a dielectric substrate 20 so to be obliquely arranged in relation to an orthogonal axis of the dielectric substrate, the patch conductor having an elliptic shape; a microstrip line 40 for feeding power to a bottom part of the patch conductor; and a ground conductor plate 50 formed on a back surface of the dielectric substrate at a position thereof that is not overlapped with the patch conductor. By forming the patch conductor to be inclined only by ?, circular polarization characteristics in which axial ratio is 3 dB or less are given and the wideband such that the frequency bandwidth in which VSWR characteristics are 2 or less is 2 through 5 GHz and the wideband in UWB High band can be attained. The antenna characteristics in which any radiation directivity on the zenith direction does not depend on the frequency are obtained.

Abstract: A series of fluorine-containing bisphosphonic acids in which an alkylamine side chain is added, a series of fluorine-containing bisphosphonic acids in which an amino group substituted by a heterocyclic group or a heterocyclic group containing a nitrogen atom is added, to the carbon atom of P—C(F)—P, and a series of fluorine-containing bisphosphonate derivatives in which the acid moiety thereof is esterified by an alkoxymethyl group such as POM group, n-butanoyloxymethyl (BuOM) group and the like, that is, the fluorine-containing bisphosphonic acid and fluorine-containing bisphosphonate derivative represented by the following formula (I): wherein each symbol is as defined in the DESCRIPTION, can efficiently induce proliferation of peripheral blood ?? T cells that express V?2V?2 T cell receptor having superior cytotoxicity against tumor cells and virus infected cells, immunize tumor cells and virus infected cells, and can induce cytotoxicity by ?? T cells.

Abstract: According to one embodiment, there is provided a nucleic acid primer set that amplifies a ZEBOV gene. An F1 sequence includes at least 13 consecutive bases included in SEQ ID NO: 31 or 64. An F2 sequence includes at least 13 bases included in SEQ ID NO: 62 or 63. An F3 sequence includes at least 13 bases included in SEQ ID NO: 29, 36, 38, 55, 56, 57, 58, 59, 60, 61 or 61. A B1c sequence includes at least 13 bases included in SEQ ID NO: 68, 69, 70, 71, 72, 73, 74 or 75. A B2c sequence includes at least 13 bases included in SEQ ID NO: 65 or 66. A B3c sequence includes at least 13 bases included in SEQ ID NO: 34, 67, 82 or 83.

Abstract: The present invention provides a or therapeutic agent for HAM, containing pentosan polysulfate or a pharmaceutically acceptable salt thereof as an active ingredient. The present invention also provides an agent for improving a HAM-associated movement disorder, containing pentosan polysulfate or a pharmaceutically acceptable salt thereof as an active ingredient.

Abstract: The invention provides nucleotide sequences that function as enhancers and induce osteoblast-specific expression, expression vectors comprising such an enhancer, a promoter, and a gene containing a coding region, as well as screening methods utilizing such expression vectors.

Abstract: The present invention relates to a composition containing as its main component proanthocyanidin oligomer to which a substance having a phloroglucinol ring structure or resorcinol ring structure has been bonded and reduced in the molecular weight, which is obtained by heating plant materials containing proanthocyanidin polymer or extract thereof with a substance having a phloroglucinol ring structure or resorcinol ring structure in an acidic aqueous solution, production method thereof, and uses of the composition in health products and pharmaceutical products. According to the invention, proanthocyanidin oligomer having physiological activity, to which a substance having a phloroglucinol ring structure or resorcinol ring structure has been bonded and reduced in the molecular weight to such a level that the oligomer can be absorbed into living body, which has been conventionally difficult to obtain at high yield from plant raw materials, can be produced efficiently and easily.

Abstract: The invention provides a method of treating chronic pain by administering an effective amount of a low-molecular weight compound that inhibits the enzyme activity of autotaxin to a subject in need thereof, thereby treating chronic pain in the subject. The chronic pain preferably is fibromyalgia, chronic fatigue syndrome, or hypersensitivity colitis.

Abstract: The present invention provides a non-human mammal deficient in the expression of prothymosin ? gene in the striatum and a screening method for a prophylactic/therapeutic drug for Huntington's disease and the like, which uses the animal.

Abstract: The invention provides an antigen or drug delivery complex containing a complex of an antigen or drug and a cationic molecule, and an anionic molecule encapsulating the same. The antigen or drug delivery complex can be used as a main component of a drug delivery system that delivers various antigens and drugs to a particular cell or organ.

Abstract: The invention provides a method of ameliorating a blood-brain barrier disorder, as well as a method of treating a disease accompanied by a blood-brain barrier disorder and a method of treating a cerebral ischemic disease, by administering a prothymosin ?, or a protein or polypeptide possessing the same function as the prothymosin ?. The invention also provides polypeptides useful in the context of the aforesaid methods.

Abstract: Provided is a process for producing an optically active compound represented by Formula (3): (wherein R1 is an alkyl group, an alkynyl group, an alkenyl group, an aliphatic heterocyclic group, a cycloalkyl group, an aryl group, an aralkyl group, or an aromatic heterocyclic group, and any hydrogen atom of R1 may be replaced with a substituent; R2 is a hydrogen atom or a group which is not reactive in the reaction below; and * represents a chiral center) or a salt thereof by subjecting a compound represented by Formula (1): (wherein R1 and R2 have the same meanings as defined in Formula (3)) to a ring closure reaction in the presence of a chiral ligand having 1 or more coordination sites, a Lewis acid represented by Formula (2): MmZn??(2) (wherein M is a metal ion, Z is a counter anion of M, and m and n are integers of 1 to 4), and a sulfonyl halide having an optionally substituted alkyl or phenyl group.

Abstract: The invention provides a method of detecting uracil. The method comprises reacting uracil with a compound represented by the formula (I) in the presence of an oxidant and a base to produce a fluorescent compound represented by the formula (II).